Loading...
•
Dec 31, 2021
Prothena Q4 2021 Earnings Report
Prothena reported financial results for the fourth quarter and full year 2021.
Key Takeaways
Prothena reported a net loss of $33.2 million for the fourth quarter of 2021, compared to a net loss of $30.7 million for the fourth quarter of 2020. Total revenue for the fourth quarter of 2021 was $1.2 million, compared to $0.4 million for the fourth quarter of 2020. The company's cash and restricted cash position was $580.4 million as of December 31, 2021.
Net cash used in operating and investing activities was $22.8 million in the fourth quarter.
Quarter-end cash and restricted cash position was $580.4 million.
Reached SPA agreement with FDA for confirmatory Phase 3 study of birtamimab and initiated the study in Mayo Stage IV patients with AL amyloidosis.
Received $80 million option payment from Bristol Myers Squibb for U.S. license to PRX005.
Revenue by Segment
Forward Guidance
The Company expects the full year 2022 net cash used in operating and investing activities to be $120 to $132 million, which includes an expected $40 million clinical milestone payment from Novo Nordisk and expects to end the year with approximately $454 million in cash, cash equivalents and restricted cash (midpoint).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...